AML1/ETO proteins control POU4F1/BRN3A expression and function in t(8;21) acute myeloid leukemia.
A variety of genetic lesions, including chromosomal translocations, internal tandem duplications, and mutations, have been described in acute myeloid leukemia (AML). Expression profiling has shown that chromosomal translocations, in particular, are associated with distinctive patterns of gene expression. AML exhibiting the translocation t(8;21), which fuses the AML1 and ETO genes, has such a characteristic expression profile. One gene whose expression is highly correlated with the presence of the AML1/ETO fusion is POU4F1, which encodes the POU homeodomain transcription factor BRN3A. Here we show using specific siRNA in t(8;21) cells and overexpression studies in progenitor cells that AML1/ETO promotes expression of POU4F1/BRN3A. This effect requires DNA-binding function of AML1/ETO, and accordingly, AML1/ETO is bound to the POU4F1 locus in t(8;21) cells. Functionally, whereas overexpression of Brn3a in murine hematopoietic progenitor cells induces terminal myeloid differentiation, coexpression of AML1/ETO or AML1/ETO9a blocks this effect. Furthermore, Brn3a reduction by shRNA impairs AML1/ETO-induced immortalization of murine progenitors. In summary, we identify POU4F1/BRN3A as a novel potential upregulated AML1/ETO target gene whose dramatically high expression may cooperate with AML1/ETO in t(8;21) cells.
Dunne
Jenny
J
Cancer Research UK Medical Oncology Unit, Barts and the London School of Medicine and Dentistry, University of London, London, United Kingdom.
Gascoyne
Duncan M
DM
Lister
T Andrew
TA
Brady
Hugh J M
HJ
Heidenreich
Olaf
O
Young
Bryan D
BD
D000328:Adult; D000818:Animals; D001483:Base Sequence; D015153:Blotting, Western; D002454:Cell Differentiation; D047369:Chromatin Immunoprecipitation; D002891:Chromosomes, Human, Pair 21 / Q000235:genetics; D002898:Chromosomes, Human, Pair 8 / Q000235:genetics; D050676:Core Binding Factor Alpha 2 Subunit / Q000235:genetics / Q000378:metabolism*; D024202:Electrophoretic Mobility Shift Assay; D053595:Embryonic Stem Cells / Q000166:cytology / Q000502:physiology; D005333:Fetus; D005455:Fluorescent Antibody Technique; D006412:Hematopoietic Stem Cells / Q000502:physiology; D006801:Humans; D007124:Immunoenzyme Techniques; D015470:Leukemia, Myeloid, Acute / Q000235:genetics* / Q000378:metabolism* / Q000473:pathology; D008099:Liver / Q000166:cytology / Q000378:metabolism; D008156:Luciferases / Q000378:metabolism; D051379:Mice; D008969:Molecular Sequence Data; D015514:Oncogene Proteins, Fusion / Q000235:genetics / Q000378:metabolism*; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D034741:RNA, Small Interfering / Q000494:pharmacology; D000075142:RUNX1 Translocation Partner 1 Protein; D020133:Reverse Transcriptase Polymerase Chain Reaction; D050819:Transcription Factor Brn-3A / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D014162:Transfection; D014178:Translocation, Genetic / Q000235:genetics
C107844:AML1-ETO fusion protein, human; D050676:Core Binding Factor Alpha 2 Subunit; D015514:Oncogene Proteins, Fusion; C494188:POU4F1 protein, human; C494189:Pou4f1 protein, mouse; D012333:RNA, Messenger; D034741:RNA, Small Interfering; D000075142:RUNX1 Translocation Partner 1 Protein; D050819:Transcription Factor Brn-3A; D008156:Luciferases
J Biol Chem. 1995 Jun 30;270(26):15858-63
7797590
Proc Natl Acad Sci U S A. 2004 Oct 19;101(42):15184-9
15477599
Nat Med. 2002 Jul;8(7):743-50
12091906
Science. 1999 Feb 19;283(5405):1129-30
10075573
Leukemia. 2004 Jul;18(7):1238-45
15152269
Br J Haematol. 2005 Feb;128(3):318-23
15667533
Blood. 2007 Aug 1;110(3):799-805
17412887
Blood. 2009 Jan 22;113(4):883-6
19036704
Oncogene. 2001 Sep 10;20(40):5660-79
11607817
J Clin Invest. 2003 Dec;112(11):1751-61
14660751
Nat Med. 2006 Aug;12(8):945-9
16892037
Blood. 2002 Jan 1;99(1):15-23
11756147
Genes Dev. 2003 Sep 15;17(18):2298-307
12952893
Mol Cell Biol. 2002 Aug;22(15):5506-17
12101243
Blood. 2007 May 15;109(10):4432-40
17244680
Oncogene. 2007 Nov 8;26(51):7231-9
17533375
Proc Natl Acad Sci U S A. 2005 Mar 15;102(11):4016-21
15731354
Nucleic Acids Res. 1993 Dec 25;21(25):5921-9
8290353
J Clin Invest. 2005 Aug;115(8):2159-68
16025155
Oncogene. 2004 May 6;23(21):3830-40
15021903
Bioinformatics. 2005 Jul 1;21(13):2933-42
15860560
Development. 2003 Jan;130(1):111-21
12441296
J Biol Chem. 2001 Feb 16;276(7):5204-12
11053412
Nat Immunol. 2009 Oct;10(10):1118-24
19749763
Leukemia. 2007 Dec;21(12):2495-505
17898786
Development. 2003 Aug;130(15):3525-34
12810599
Proc Natl Acad Sci U S A. 2002 Jul 23;99(15):10008-13
12105272
Nature. 1996 Dec 12;384(6609):574-7
8955272
EMBO J. 2003 Jun 2;22(11):2798-809
12773394
Blood. 1991 May 1;77(9):2031-6
2018839
Oncogene. 2006 Oct 5;25(45):6067-78
16652140
Blood. 2004 Dec 1;104(12):3679-87
15226186
Genes Chromosomes Cancer. 2003 Jun;37(2):149-58
12696063
Proc Natl Acad Sci U S A. 2005 Jan 25;102(4):1104-9
15650049
Mol Cell Biol. 2008 May;28(10):3502-12
18332109
Mech Dev. 1995 Nov;53(3):291-304
8645597
Blood. 2000 Sep 15;96(6):2108-15
10979955
Blood. 2003 Apr 15;101(8):3157-63
12480707
Oncogene. 2003 Jun 12;22(24):3685-97
12802276
Nat Genet. 1997 Mar;15(3):303-6
9054947
Blood. 2000 Dec 1;96(12):3939-47
11090081
Oncogene. 2004 Dec 2;23(56):9070-81
15489901
Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11950-5
8876243
J Cell Biol. 2004 Oct 25;167(2):257-67
15492043
Int J Cancer. 2008 Sep 15;123(6):1240-5
18623087